An international study reveals that the drug can reverse liver damage in patients. An international study led by researchers ...

New research reveals that semaglutide significantly improves liver health in MASH patients. A new study published in the New ...

GSK plans to purchase an experimental drug for the liver disease MASH from Boston Pharmaceuticals for $1.2 billion upfront.

Researchers shed light on the "dark matter" of the gut, revealing a species of fungus that could potentially help counter ...

High levels of liver enzymes in your blood may sometimes indicate an underlying liver condition that requires medical ...

Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) has demonstrated sustained efficacy in a late-stage trial of patients with ...

Mar. 11, 2025 — Metabolic dysfunction-associated steatohepatitis (MASH) is a polygenic disorder ... Novel Therapeutics of Nonalcoholic Fatty Liver Diseases Mar. 6, 2025 — Investigators have ...

With its purchase of Boston Pharmaceuticals' drug, GSK extends a streak of dealmaking it's undertaken to build a liver ...

GSK acquires Boston Pharmaceuticals' efimosfermin for up to $2 billion, targeting liver diseases like MASH and ALD.

GSK has agreed to pay $1.2 billion upfront to acquire rights to efimosfermin from Cambridge, Massachusetts-based Boston ...

A groundbreaking study from the University of Oklahoma reveals that the hormone FGF21 can reverse fatty liver disease by ...

GSK will gain access to efimosfermin by acquiring Boston’s subsidiary BP Asset IX for $1.2bn upfront and up to $800m in ...